https://www.selleckchem.com/products/U0126.html
4 months in RCC and 2.3 months in UC (p=0.03). If the disease did not progress in 4 months (long SD subgroup), the DoSD (11.0 months) was comparable to the duration of response (12.9 months) in patients who achieved a complete or partial response to PD-1/PD-L1 inhibitors. In addition to the cancer type, the clinical factors associated with short DoSD were liver metastases (p=0.003), neutrophil-lymphocyte ratio (NLR)4.0 (p=0.001), and platelet-lymphocyte ratio (PLR)194 (p=0.003). For RCC patients with SD to PD-1/PD-L1 inhibitors, i
Like
Comment
Share
